Teva faces EU antitrust probe over MS drug Copaxone
pharmaphorum
MARCH 5, 2021
billion in annual sales it generated during its peak year in 2013. The Commission will also examine whether Teva may have launched a communication campaign to create a “false perception” about the health risks of prescribing generic competitors, aimed at healthcare professionals and hospitals.
Let's personalize your content